Purpose: The aim of the study was to observe the efficacy and safety of injection antiVEGF as rescue therapy in sight threatening threshold ROP as monotherapy or in combination with conventional laser therapy. Patients and methods: This was a retrospective observational study. 20 eyes of 13 preterm infants suffering from ROP suffering from threshold ROP, and they were treated with intravitreal injection Bevacizumab alone or combinedly with conventional laser photocoagulation were included. All eyes had stage III zone 2 with 'plus disease'. All eyes had a follow up period of atleast 3 month following treatment. On follow up detail fundus examination with documentation and retinoscopy was done. Results : The study included 20 eyes of 9 male infants and 4 female infants. The gestational ages ranged from 26 to 35 weeks (mean 29.15 weeks), and the birth weights ranged from 830 to 1600 g (mean1257 g). All 20 eyes had stage III zone 2 ROP with plus disease; All study eyes following one or both treatment modalities remained stable during followup. Except 2 eyes develop temporal macular dragging which were treated combinedly with injection Bevacizumab and laser photocoagulation. Retinoscopic value was mean -3.44 and -2.35 diopter spherical equivalent for Bevacizumab alone and combinedly treated group respectively. Conclusion: Intravitreal injection Bevacizumab alone or combinedly with laser photocoagulation treatment is effective for sight threatening ROP and does not seem to be associated with serious ocular or systemic adverse events